Why Is NovoCure Limited (NVCR) Under Investigation?

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NovoCure Limited (“Novocure” or “the Company”) (NASDAQ: NVCR). Investors who purchased Novocure securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Novocure has violated federal securities laws.

What Potential Securities Violations Is BG&G Investigating?

On October 30, 2025, NovoCure touted the benefits of starting Tumor Treating Fields (“TTFields”) therapy earlier in the treatment cycle. But the Company’s Phase 3 TRIDENT trial failed to find a statistically significant improvement with this approach. Following this news, Novocure’s stock price dropped 20% on June 18, 2026.

What Should NovoCure Limited (NVCR) Investors Do?

If you are aware of any facts relating to this investigation or purchased Novocure securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911